Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen

Documenti analoghi

• 5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
  di: Lazzarin, A, et al.
  Pubblicazione: (2010)
• Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir
  di: Edelman, E. Jennifer, et al.
  Pubblicazione: (2012)
• Antiretroviral regimen complexity as a predictor of adherence
  di: Boyle, C, et al.
  Pubblicazione: (2010)
• Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the US
  di: Sax, PE, et al.
  Pubblicazione: (2010)
• Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
  di: Chua, Arlene C, et al.
  Pubblicazione: (2012)